Zymeworks Stock Earnings Reports

Zymeworks reported Q1 2026 progress across partnered and wholly owned assets, highlighted by a near-term regulatory catalyst: an August 25, 2026 PDUFA date in the U.S. for zanidatamab in first-line HER2-positive GEA and an sBLA filing in China. Management emphasized the potential for significant milestone payments (notably $250M U.S. and $15M China on approval) and growing royalty streams tied to zanidatamab/zivhera commercialization through partners (Jazz, B1). R&D momentum was showcased at AACR with 3 new preclinical pan‑RAS ADC candidates and encouraging Phase I data for ZW191 (folate receptor-α ADC) showing substantial activity in heavily pretreated ovarian and endometrial cohorts and a manageable safety profile; a dose-optimization cohort is fully enrolled. ZW251 (GPC3 ADC) expansion into additional tumor types was discussed, and the IND for ZW1528 (IL‑33/IL‑4Rα bispecific) timing was deferred to 2027 to better refine clinical strategy. Financially, Q1 revenue was $2.4M (down YoY due to fewer 2025 nonrecurring milestones), operating expenses were $49.5M, and net loss was $44.2M. Cash and marketable securities were $403.8M at quarter end; the company has repurchased ~$95.8M of its $125M buyback authorization to date. Management expects current cash plus anticipated regulatory milestones (~$440M) to fund operations beyond 2028 assuming full repurchase execution. Leadership additions and a disciplined capital-allocation approach (royalty aggregation + selective share repurchases and potential transactions/partnerships) were reiterated as central to the company’s strategy.